Clinical & translational immunology · 2026
Adaptive immune response to the autoantigen LL-37 differentiates atherosclerotic cardiovascular disease phenotypes.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dimayuga Paul C, Chyu Kuang-Yuh, Zhou Jianchang, Zhao Xiaoning, Wei Janet, Cercek Bojan, Shah Prediman K
Аннотация
UNLABELLED: Atherosclerosis is the common underlying pathology in atherosclerotic cardiovascular disease (ASCVD) phenotypes of myocardial infarction (MI), stroke or peripheral artery disease (PAD). Single immune cell profiling of atherosclerotic plaques demonstrates a site-specific immune profile associated with the ASCVD phenotype, and LL-37 is a reported autoantigen in atherosclerosis.
OBJECTIVE: To investigate whether the immune response to LL-37 would be common among different ASCVD phenotypes.
METHODS: Peripheral blood mononuclear cells (PBMCs) and plasma were collected from stable ASCVD patients enrolled within 12 months after MI or stroke or diagnosed with PAD. A subgroup of post-acute patients provided PBMCs at follow-up (14.7 ± 3.6 months). T-cell response to LL-37 was profiled using activation-induced markers. LL-37 IgG, immune complex (IC) levels and subclass were evaluated with ELISA. LDL is a reported binding partner of LL-37 in plasma. Therefore, cross-reactivity of LL-37 IgG-ICs with native LL-37 or LL-37 complexed with LDL (LL-37_LDL) was assessed using immune depletion.
RESULTS: LL-37 provokes increased CD4+CD25+CD134+ T-cell response in stable post-MI patients whereas CD8+CD25+CD69+ T cells were reduced in PAD. CD4+ T-cell response to LL-37 in post-MI patients persisted at follow-up with increased CD4+CD25+CD69+FoxP3+ T regulatory cells while post-stroke patients had increased CD8+CD134+ T cells. LL-37 IgG-ICs were significantly increased in ASCVD patients with IgG3 subclass reduced in post-MI compared to post-stroke. Immune-depletion showed cross-reactivity of LL-37 IgG-ICs with both native LDL and LL-37_LDL only in post-MI plasma.
CONCLUSION: LL-37 antigen specific profiling of immune response may differentiate various ASCVD phenotypes and provide mechanistic insight in pathophysiology.
OBJECTIVE: To investigate whether the immune response to LL-37 would be common among different ASCVD phenotypes.
METHODS: Peripheral blood mononuclear cells (PBMCs) and plasma were collected from stable ASCVD patients enrolled within 12 months after MI or stroke or diagnosed with PAD. A subgroup of post-acute patients provided PBMCs at follow-up (14.7 ± 3.6 months). T-cell response to LL-37 was profiled using activation-induced markers. LL-37 IgG, immune complex (IC) levels and subclass were evaluated with ELISA. LDL is a reported binding partner of LL-37 in plasma. Therefore, cross-reactivity of LL-37 IgG-ICs with native LL-37 or LL-37 complexed with LDL (LL-37_LDL) was assessed using immune depletion.
RESULTS: LL-37 provokes increased CD4+CD25+CD134+ T-cell response in stable post-MI patients whereas CD8+CD25+CD69+ T cells were reduced in PAD. CD4+ T-cell response to LL-37 in post-MI patients persisted at follow-up with increased CD4+CD25+CD69+FoxP3+ T regulatory cells while post-stroke patients had increased CD8+CD134+ T cells. LL-37 IgG-ICs were significantly increased in ASCVD patients with IgG3 subclass reduced in post-MI compared to post-stroke. Immune-depletion showed cross-reactivity of LL-37 IgG-ICs with both native LDL and LL-37_LDL only in post-MI plasma.
CONCLUSION: LL-37 antigen specific profiling of immune response may differentiate various ASCVD phenotypes and provide mechanistic insight in pathophysiology.